239 related articles for article (PubMed ID: 26832958)
1. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Investigation of Metastasis-Related Chemokines in Deep-Infiltrating Endometriosis and Compromised Pelvic Sentinel Lymph Nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Kaufmann AM; Chiantera V; Mechsner S
Reprod Sci; 2015 Dec; 22(12):1632-42. PubMed ID: 26169037
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
5. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
6. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
7. BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.
Stamp JP; Gilks CB; Wesseling M; Eshragh S; Ceballos K; Anglesio MS; Kwon JS; Tone A; Huntsman DG; Carey MS
Int J Gynecol Cancer; 2016 Jun; 26(5):825-32. PubMed ID: 27051059
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of genes associated with stemness and cancer in endometria and endometrioma in a subset of women with endometriosis.
Ponandai-Srinivasan S; Andersson KL; Nister M; Saare M; Hassan HA; Varghese SJ; Peters M; Salumets A; Gemzell-Danielsson K; Lalitkumar PGL
Hum Reprod; 2018 Oct; 33(10):1924-1938. PubMed ID: 30020448
[TBL] [Abstract][Full Text] [Related]
9. Endometrial vezatin and its association with endometriosis risk.
Holdsworth-Carson SJ; Fung JN; Luong HT; Sapkota Y; Bowdler LM; Wallace L; Teh WT; Powell JE; Girling JE; Healey M; Montgomery GW; Rogers PA
Hum Reprod; 2016 May; 31(5):999-1013. PubMed ID: 27005890
[TBL] [Abstract][Full Text] [Related]
10. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
[TBL] [Abstract][Full Text] [Related]
11. Iatrogenic endometriosis harbors somatic cancer-driver mutations.
Lac V; Verhoef L; Aguirre-Hernandez R; Nazeran TM; Tessier-Cloutier B; Praetorius T; Orr NL; Noga H; Lum A; Khattra J; Prentice LM; Co D; Köbel M; Mijatovic V; Lee AF; Pasternak J; Bleeker MC; Krämer B; Brucker SY; Kommoss F; Kommoss S; Horlings HM; Yong PJ; Huntsman DG; Anglesio MS
Hum Reprod; 2019 Jan; 34(1):69-78. PubMed ID: 30428062
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: from oxidative stress to fibrosis.
González-Foruria I; Santulli P; Chouzenoux S; Carmona F; Chapron C; Batteux F
Mol Hum Reprod; 2017 Jul; 23(7):488-499. PubMed ID: 28486700
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.
Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE
Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
15. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
16. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
17. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
18. Total circulating microparticle levels are increased in patients with deep infiltrating endometriosis.
Munrós J; Martínez-Zamora MA; Tàssies D; Coloma JL; Torrente MA; Reverter JC; Carmona F; Balasch J
Hum Reprod; 2017 Feb; 32(2):325-331. PubMed ID: 27989989
[TBL] [Abstract][Full Text] [Related]
19. Spread of endometriosis to pelvic sentinel lymph nodes: gene expression analysis.
Bürkle B; Notscheid NK; Scheich J; Hefler L; Tempfer CB; Horvat R; Rezniczek GA
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):370-5. PubMed ID: 23639674
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing the progression of an endometrioma: Benign or malignant?
Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
